[1]乔斌超,贾永平,陈小平.心肌肌球蛋白结合蛋白-C在心血管疾病中的作用研究进展[J].新乡医学院学报,2024,(3):286-290.[doi:10.7683/xxyxyxb.2024.03.016]
　QIAO Binchao,JIA Yongping,CHEN Xiaoping.Research progress on the role of cardiac myosin binding protein-C in cardiovascular diseases[J].Journal of Xinxiang Medical University,2024,(3):286-290.[doi:10.7683/xxyxyxb.2024.03.016]
点击复制

心肌肌球蛋白结合蛋白-C在心血管疾病中的作用研究进展
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
期数:
2024年3
页码:
286-290
栏目:
综述
出版日期:
2024-03-05

文章信息/Info

Title:
Research progress on the role of cardiac myosin binding protein-C in cardiovascular diseases
作者:
乔斌超1; 贾永平2; 陈小平3
（1.山西医科大学第一临床医学院，山西　太原　030001；2.山西医科大学第一医院心内科，山西　太原　030001；3.山西医科大学附属太原中心医院心内科，山西　太原　030009）
Author(s):
QIAO Binchao1; JIA Yongping2; CHEN Xiaoping3
(1.The First Clinical Medical College of Shanxi Medical University,Taiyuan 030001,Shanxi Province,China;2.Department of Cardiology,the First Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi Province,China;3.Department of Cardiology,Taiyuan Central Hospital Affiliated to Shanxi Medical University,Taiyuan 030009,Shanxi Province,China)
关键词:
心肌肌球蛋白结合蛋白-C; 心血管疾病; 作用机制
Keywords:
cardiac myosin binding protein-C; cardiovascular disease; mechanism of action
分类号:
R542.2
DOI:
10.7683/xxyxyxb.2024.03.016
文献标志码:
A
摘要:
心肌肌球蛋白结合蛋白-C（cMyBP-C）作为心肌粗肌丝的重要组成部分，可以通过磷酸化或去磷酸化调节横桥循环速率，参与心肌收缩舒张功能。cMyBP-C在急性心肌梗死、心肌病、心力衰竭、主动脉瓣狭窄、高血压心肌肥厚、心肌炎等心血管疾病的发生发展过程中发挥重要作用，但具体作用机制尚未完全阐明。本文就cMyBP-C在心血管疾病中的作用研究进展进行综述，以期为心血管疾病的诊断、治疗及预后评估提供参考。
Abstract:
Cardiac myosin binding protein-C (cMyBP-C),as an important component of myocardium coarse filaments,can regulate cross-bridge circulation through phosphorylation or dephosphorylation and participates in myocardial systolic and diastolic functions.cMyBP-C plays an important role in the occurrence and development of cardiovascular diseases (CVDs) such as acute myocardial infarction,cardiomyopathy,heart failure,aortic stenosis,hypertensive myocardial hypertrophy,and myocarditis,but the specific mechanism has not been fully clarified.This article reviews the research progress on the role of cMyBP-C in CVDs,in order to provide references for the diagnosis,treatment and prognosis evaluation of CVDs.

参考文献/References:

［1］　《中国心血管健康与疾病报告2021》编写组.《中国心血管健康与疾病报告2021》概述［J］.中国心血管病研究,2022,20(7):577-596.
THE WRITING COMMITTEE OF THE REPORT ON CARDIOVASCULAR HEALTH AND DISEASES IN CHINA 2021.Key points of Report on Cardiovascular Health and Diseases in China 2021［J］.Chin J Cardiovasc Res,2022,20(7):577-596.
［2］　SADAYAPPAN S,DE TOMBE P P.Cardiac myosin binding protein-C as a central target of cardiac sarcomere signaling:a special mini review series［J］.Pflugers Arch,2014,466(2):195-200.
［3］　DESAI D A,RAO V J,JEGGA A G,et al.Heterogeneous distribution of genetic mutations in myosin binding protein-C paralogs［J］.Front Genet,2022,13:896117.
［4］　PERAZZA L R,WEI G,THOMPSON L V.Fast and slow skeletal myosin binding protein-C and aging［J］.Geroscience,2023,45(2):915-929.
［5］　HUANG X,TORRE I,CHIAPPI M,et al.Cryo-electron tomography of intact cardiac muscle reveals myosin binding protein-C linking myosin and actin filaments［J］.J Muscle Res Cell Motil,2023,44(3):165-178.
［6］　KANASSATEGA R S,BUNCH T A,LEPAK V C,et al.Human cardiac myosin-binding protein C phosphorylation- and mutation-dependent structural dynamics monitored by time-resolved FRET［J］.J Mol Cell Cardiol,2022,166:116-126.
［7］　NELSON S,BECK-PREVIS S,SADAYAPPAN S,et al.Myosin-binding protein C stabilizes,but is not the sole determinant of SRX myosin in cardiac muscle［J］.J Gen Physiol,2023,155(4):e202213276.
［8］　RISI C M,VILLANUEVA E,BELKNAP B,et al.Cryo-electron microscopy reveals cardiac myosin binding protein-C M-domain intera-ctions with the thin filament［J］.J Mol Biol,2022,434(24):167879.
［9］　TOUMA A M,TANG W,RASICCI D V,et al.Nanosurfer assay dissects β-cardiac myosin and cardiac myosin-binding protein C interactions［J］.Biophys J,2022,121(12):2449-2460.
［10］　MAMIDI R,GRESHAM K S,LI J,et al.Cardiac myosin binding protein-C Ser302 phosphorylation regulates cardiac β-adrenergic reserve［J］.Sci Adv,2017,3(3):e1602445.
［11］　MCNAMARA J W,SINGH R R,SADAYAPPAN S.Cardiac myosin binding protein-C phosphorylation regulates the super-relaxed state of myosin［J］.Proc Natl Acad Sci USA,2019,116(24):11731-11736.
［12］　LYNCH T L,KUMAR M,MCNAMARA J W,et al.Amino terminus of cardiac myosin binding protein-C regulates cardiac contractility［J］.J Mol Cell Cardiol,2021,156:33-44.
［13］　LIANG C,AISA Z,SUN L,et al.Cardiac ischemic preconditioning promotes cMyBP-C phosphorylation by inhibiting the calpain-mediated proteolysis［J］.Exp Cell Res,2023,433(2):113859.
［14］　KUMAR M,HAGHIGHI K,KRANIAS E G,et al.Phosphorylation of cardiac myosin-binding protein-C contributes to calcium homeostasis［J］.J Biol Chem,2020,295(32):11275-11291.
［15］　WONG F L,BUNCH T A,LEPAK V C,et al.Cardiac myosin-binding protein C N-terminal interactions with myosin and actin filaments:opposite effects of phosphorylation and M-domain mutations［J］.J Mol Cell Cardiol,2024,186:125-137.
［16］　SUAY-CORREDERA C,ALEGRE-CEBOLLADA J.The mechanics of the heart:zooming in on hypertrophic cardiomyopathy and cMyBP-C［J］.FEBS Lett,2022,596(6):703-746.
［17］　KLOSKA S M,KOZINSKI M,STEFANSKA A,et al.Reference values and biological determinants for cardiac myosin-binding protein C concentrations assessed with an enzyme-linked immunosorbent assay［J］.J Med Biochem,2023,42(4):665-674.
［18］　GOVINDAN S,KUSTER D W,LIN B,et al.Increase in cardiac myosin binding protein-C plasma levels is a sensitive and cardiac-specific biomarker of myocardial infarction［J］.Am J Cardiovasc Dis,2013,3(2):60-70.
［19］　KAIER T E,TWERENBOLD R,PUELACHER C,et al.Direct comparison of cardiac myosin-binding protein C with cardiac troponins for the early diagnosis of acute myocardial infarction［J］.Circulation,2017,136(16):1495-1508.
［20］　KAIER T E,STENGAARD C,MARJOT J,et al.Cardiac myosin-binding protein C to diagnose acute myocardial infarction in the pre-hospital setting［J］.J Am Heart Assoc,2019,8(15):e013152.
［21］　KUSTER D W,CARDENAS-OSPINA A,MILLER L,et al.Release kinetics of circulating cardiac myosin binding protein-C following cardiac injury［J］.Am J Physiol Heart Circ Physiol,2014,306(4):H547-556.
［22］　朱吉刚.4种血清心肌标志物在AMI患者中的水平及其临床意义分析［J］.国际检验医学杂志,2018,39(13):1642-1645.
ZHU J G.Levels and clinical significance of four serum myocardial markers in patients with AMI［J］.Int J Lab Med,2018,39(13):1642-1645.
［23］　MARIAN A J,BRAUNWALD E.Hypertrophic cardiomyopathy:genetics,pathogenesis,clinical manifestations,diagnosis,and therapy［J］.Circ Res,2017,121(7):749-770.
［24］　GELPI ACEVEDO L M,SALINAS A L,POLANCO J S,et al.A narrative review of the pathophysiology and treatment of hypertrophic cardiomyopathy［J］.South Med J,2022,115(12):926-929.
［25］　TOEPFER C N,WAKIMOTO H,GARFINKEL A C,et al.Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin［J］.Sci Transl Med,2019,11(476):1-20.
［26］　PRONDZYNSKI M,KRMER E,LAUFER S D,et al.Evaluation of MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-Derived cardiomyocytes［J］.Mol Ther Nucleic Acids,2017,7:475-486.
［27］　SANTINI L,COPPINI R,CERBAI E.Ion channel impairment and myofilament Ca2+ sensitization:two parallel mechanisms underlying arrhythmogenesis in hypertrophic cardiomyopathy［J］.Cells,2021,10(10):2789.
［28］　TOIB A,ZHANG C,BORGHETTI G,et al.Remodeling of repolarization and arrhythmia susceptibility in a myosin-binding protein C knockout mouse model［J］.Am J Physiol Heart Circ Physiol,2017,313(3):H620-H630.
［29］　RAPEZZI C,AIMO A,BARISON A,et al.Restrictive cardiomyo-pathy:definition and diagnosis［J］.Eur Heart J,2022,43(45):4679-4693.
［30］　CIMIOTTI D,BUDDE H,HASSOUN R,et al.Genetic restrictive cardiomyopathy:causes and consequences-an integrative approach［J］.Int J Mol Sci,2021,22(2):558.
［31］　WU W,LU C X,WANG Y N,et al.Novel phenotype-genotype correlations of restrictive cardiomyopathy with myosin-binding protein C (MYBPC3) gene mutations tested by next-generation sequencing［J］.J Am Heart Assoc,2015,4(7):e001879.
［32］　PARK J,LEE J M,CHO J S.Phenotypic diversity of cardiomyopathy caused by an MYBPC3 frameshift mutation in a Korean family:a case report［J］.Medicina,2021,57(3):281-287.
［33］　CHEN S N,MESTRONI L,TAYLOR M R G.Genetics of dilated cardiomyopathy［J］.Curr Opin Cardiol,2021,36(3):288-294.
［34］　JIANG J,BURGON P G,WAKIMOTO H,et al.Cardiac myosin binding protein C regulates postnatal myocyte cytokinesis［J］.Proc Natl Acad Sci USA,2015,112(29):9046-9051.
［35］　LYNCH T L 4TH,ISMAHIL M A,JEGGA A G,et al.Cardiac inflammation in genetic dilated cardiomyopathy caused by MYBPC3 mutation［J］.J Mol Cell Cardiol,2017,102:83-93.
［36］　黄露,胡增美,侯佳华,等.MicroRNA在心力衰竭中的调控作用及中西药物干预研究进展［J］.解放军医学杂志,2023,48(3):331-338.
HUANG L,HU Z M,HOU J H,et al.Regulatory role of miRNA in heart failure and research progress of intervention by traditional Chinese and western medicine［J］.Med J Chin People′s Liberation Army,2023,48(3):331-338.
［37］　饶小娇,边洋,王彬宇,等.老年慢性心力衰竭患者血清中胰岛素样生长因子-1和肾损伤分子-1表达水平变化及对预后的影响［J］.新乡医学院学报,2023,40(4):324-328.
RAO X J,BIAN Y,WANG B Y,et al.Changes of serum insulin-like growth factor-1 and kidney injury molecule-1 levels in elderly patients with chronic heart failure and their influence on prognosis［J］.J Xinxiang Med Univ,2023,40(4):324-328.
［38］　HOU L,KUMAR M,ANAND P,et al.Modulation of myosin by cardiac myosin binding protein-C peptides improves cardiac contractility in ex-vivo experimental heart failure models［J］.Sci Rep,2022,12(1):4337.
［39］　TONG C W,NAIR N A,DOERSCH K M,et al.Cardiac myosin-binding protein-C is a critical mediator of diastolic function［J］.Pflugers Arch,2014,466(3):451-457.
［40］　ROSAS P C,LIU Y,ABDALLA M I,et al.Phosphorylation of cardiac myosin-binding protein-C is a critical mediator of diastolic function［J］.Circ Heart Fail,2015,8(3):582-594.
［41］　GRESHAM K S,STELZER J E.The contributions of cardiac myosin binding protein C and troponin I phosphorylation to β-adrenergic enhancement of in vivo cardiac function［J］.J Physiol,2016,594(3):669-686.
［42］　ANAND A,CHIN C,SHAH A S V,et al.Cardiac myosin-binding protein C is a novel marker of myocardial injury and fibrosis in aortic stenosis［J］.Heart,2018,104(13):1101-1108.
［43］　COPELAND O,MESSER A,JABBOUR A,et al.Pressure overload is associated with low levels of troponin I and myosin binding protein C phosphorylation in the hearts of patients with aortic stenosis［J］.Front Physiol,2020,11:241.
［44］　束长城,魏万林.高血压左心室肥厚的形成机制研究进展［J］.中国循证心血管医学杂志,2018,10(6):760-762.
SHU C C,WEI W L.Research progress in formation mechanism of hypertensive left ventricular hypertrophy［J］.Chin J Evid Based Cardiovasc Med,2018,10(6):760-762.
［45］　DE LA ROSA A,SHAH M,SHIOTA T,et al.Comparing echocardiographic characteristics in genotype positive-phenotype positive hypertrophic cardiomyopathy and hypertensive left ventricular hypertrophy［J］.Eur Heart J Cardiovasc Imaging,2022,23(3):340-348.
［46］　WANG Y,YOUM J B,JIN C Z,et al.Modulation of L-type Ca2+ channel activity by neuronal nitric oxide synthase and myofilament Ca2+ sensitivity in cardiac myocytes from hypertensive rat［J］.Cell Calcium,2015,58(3):264-274.
［47］　YOGESWARAN A,TROIDL C,MCNAMARA J W,et al.The C0-C1f region of cardiac myosin binding protein-C induces pro-inflammatory responses in fibroblasts via TLR4 signaling［J］.Cells,2021,10(6):1326.
［48］　LYNCH T L,SADAYAPPAN S.Surviving the infarct:a profile of cardiac myosin binding protein-C pathogenicity,diagnostic utility,and proteomics in the ischemic myocardium［J］.Proteomics Clin Appl,2014,8(7/8):569-577.
［49］　GOVINDAN S,SARKEY J,JI X,et al.Pathogenic properties of the N-terminal region of cardiac myosin binding protein-C in vitro［J］.J Muscle Res Cell Motil,2012,33(1):17-30.
［50］　LIPPS C,NGUYEN J H,PYTTEL L,et al.N-terminal fragment of cardiac myosin binding protein-C triggers pro-inflammatory responses in vitro［J］.J Mol Cell Cardiol,2016,99:47-56.

相似文献/References:

[1]吕风华,吴天赐,张素荣,等.豫北地区中老年以心血管疾病就诊患者的流行病学研究[J].新乡医学院学报,2011,28(03):334.
[2]崔朝初,卢　娜,冯超丽,等.前蛋白转化酶枯草杆菌蛋白酶9及其抑制剂在动脉粥样硬化中的作用研究进展[J].新乡医学院学报,2021,38(3):213.[doi:10.7683/xxyxyxb.2021.03.003]
[3]马春朋,刘晓丽,董雪飞,等.缺血性胸痛患者高三酰甘油血症-腰围表型与心血管疾病危险因素聚集的关系[J].新乡医学院学报,2016,33(10):901.[doi:10.7683/xxyxyxb.2016.10.017]
　MA Chun-peng,LIU Xiao-li,DONG Xue-fei,et al.Relationship between hypertriglyceridemic-waist phenotype and clustering of cardiovascular risk factors in chest pain patients[J].Journal of Xinxiang Medical University,2016,33(3):901.[doi:10.7683/xxyxyxb.2016.10.017]
[4]阮梦瑶,赵国安.纤维蛋白原与心血管疾病的相关性研究进展[J].新乡医学院学报,2020,37(5):494.[doi:10.7683/xxyxyxb.2020.05.022]
[5]高丽云,聂林坤,李　潇,等.大气细颗粒物PM2.5对心血管疾病损害机制的研究进展[J].新乡医学院学报,2018,35(7):551.[doi:10.7683/xxyxyxb.2018.07.001]
　N/A.N/A[J].Journal of Xinxiang Medical University,2018,35(3):551.[doi:10.7683/xxyxyxb.2018.07.001]
[6]余仁强,周　勤,马路一.儿童肥胖与心血管疾病危险因素的关系研究进展[J].新乡医学院学报,2016,33(1):078.[doi:10.7683/xxyxyxb.2016.01.023]
　YU Renqiang,ZHOU Qin,MA Luyi.Research Progress of the relationship between childhood obesity and risk factors of cardiovascular disease[J].Journal of Xinxiang Medical University,2016,33(3):078.[doi:10.7683/xxyxyxb.2016.01.023]
[7]郭伟丽,李　航,安　珍,等.n-3多不饱和脂肪酸对心血管疾病的防治作用及其机制研究现状[J].新乡医学院学报,2016,33(3):227.[doi:10.7683/xxyxyxb.2016.03.019]
　GUO Weili,LI Hang,AN Zhen,et al.Research status of the preventive and therapeutic effects of n-3 polyunsaturated fatty acids on cardiovascular diseases and their mechanisms[J].Journal of Xinxiang Medical University,2016,33(3):227.[doi:10.7683/xxyxyxb.2016.03.019]
[8]袁　琳,韩光亮.MiR-155在动脉粥样硬化发生发展中的作用研究进展[J].新乡医学院学报,2016,33(10):930.[doi:10.7683/xxyxyxb.2016.10.026]
　YUAN Lin,HAN Guangliang.Research progress on the role of miR-155 in the occurrence and development of atherosclerosis[J].Journal of Xinxiang Medical University,2016,33(3):930.[doi:10.7683/xxyxyxb.2016.10.026]
[9]吴聪聪,唐方明.脂蛋白磷脂酶A2与心血管疾病的相关性研究进展[J].新乡医学院学报,2016,33(12):1105.[doi:10.7683/xxyxyxb.2016.12.024]
　WU Congcong,TANG Fangming.Research progress on the correlation between lipoprotein phospholipase A2 and cardiovascular disease[J].Journal of Xinxiang Medical University,2016,33(3):1105.[doi:10.7683/xxyxyxb.2016.12.024]
[10]杨靖倩,狄亚妮,胡爽爽,等.终末期肾病患者腹膜透析后心血管疾病影响因素分析[J].新乡医学院学报,2023,40(4):333.[doi:10.7683/xxyxyxb.2023.04.007]
　YANG Jingqian,DI Yani,HU Shuangshuang,et al.Analysis of influencing factors of cardiovascular disease in patients with end-stage renal disease after peritoneal dialysis[J].Journal of Xinxiang Medical University,2023,40(3):333.[doi:10.7683/xxyxyxb.2023.04.007]

更新日期/Last Update: 2024-03-05